The first under-the-skin, long-acting risperidone injection offers a new maintenance option for adults with bipolar 1 ...
Uzedy administered once every 2 months is not recommended for the maintenance treatment of bipolar I disorder. The Food and Drug Administration (FDA) has approved Uzedy ® (risperidone extended-release ...
Lupin has received approval from the Food and Drug Administration for risperidone for extended-release injectable suspension, 25 mg per vial, 37.5 mg per vial and 50 mg per vial, single-dose vials.
FDA approves UZEDY® (risperidone) extended-release injectable suspension for subcutaneous use as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I ...
The RISE study 7 was a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of risperidone extended-release injectable suspension for subcutaneous use as a ...
The potentially devastating consequences of a relapse in patients with schizophrenia and the substantial risk of relapse associated with even partial compliance with therapy have made compliance a ...
Risperdal Consta Dosage and Administration Adult Risperidone-naive: rule out risperidone hypersensitivity before using injection. Give by deep deltoid or gluteal IM inj; alternate sides. Give with ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved a long-acting subcutaneous risperidone injection for the treatment of schizophrenia in adults.
Teva Pharmaceutical Industries Limited TEVA recently announced that the FDA has approved expanded use of its branded product, Uzedy (risperidone). The regulatory body has now approved Uzedy (50 mg, 75 ...
NAPLES, Fla., Sept. 10, 2025 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it has received approval ...
Hosted on MSN
Lupin Gains After USFDA Nod for Risperidone Injectable To Treat Schizophrenia And Bipolar I Disorder
Lupin’s shares rose 2.8% in afternoon trading after the company received a key U.S. Food and Drug Administration (FDA) approval. On Wednesday, Lupin received USFDA approval for its Abbreviated New ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results